期刊文献+

成团泛菌低分子脂多糖的急性毒性、刺激性、致敏性及遗传毒性评估 被引量:4

Evaluation of the Acute Toxicity,Irritation,Hypersensitivity and Genetic Toxicity for Lipopolysaccharides from Pantoea agglomerans (LPSp)
下载PDF
导出
摘要 本研究对成团泛菌低分子脂多糖(Pantoea agglomerans lipopolysaccharide,LPSp)的安全性进行初步评估。本研究采用一次限量法,用昆明种小鼠进行LPSp急性经口毒性试验,了解LPSp的急性毒性;采用新西兰兔分别进行LPSp急性和多次皮肤刺激性试验以及急性眼刺激性试验,了解LPSp的皮肤和粘膜刺激性;采用豚鼠进行LPSp皮肤变态反应试验,了解LPSp的致敏性;应用平板掺入法进行鼠伤寒沙门氏菌/回复突变试验和小鼠骨髓细胞微核试验考察LPSp的遗传危害。急性毒性试验结果显示,LPSp对小鼠经口一次灌胃的LD50大于5000mg/kg体重,属实际无毒级别;LPSp急性和多次皮肤刺激性试验以及急性眼刺激性试验结果显示,皮肤刺激和眼刺激积分均为0分,LPSp对皮肤无刺激性、对眼睛无急性刺激性;在皮肤变态反应试验中,LPSp在各观察时间点的皮肤变态反应积分均为0分,其致敏率均为0%,说明LPSp对豚鼠无致敏性;LPSp的鼠伤寒沙门氏菌/回复突变试验结果呈阴性(P>0.05);LPSp的小鼠骨髓细胞微核试验结果亦呈阴性,LPSp各剂量组的微核发生率与阴性对照组未见统计学差异(P>0.05),而与阳性对照组有明显差异(P<0.01)。本研究结果表明,在本实验剂量范围内,LPSp对小鼠经口毒性极低,属实际无毒级别,对家兔皮肤和眼睛无明显刺激性,对豚鼠无致敏性,对所试菌株和小鼠体细胞无诱变性和致突变性。 In this study,a serial of experiments were practiced to evaluate the safe of Pantoea agglomerans lipopolysaccharide (LPSp).Using limited does method,the acute oral toxicity test was carried out on Kunming mice to understand acute toxicity of LPSp;the skin and eye Irritation test were carried out on New Zealand Rabbits to understand the skin and eye irritation of LPSp;and the skin allergy test were carried out on guinea pig to understand the hypersensitivity of LPSp.The salmonella typhimurium/reverse mutation assay and cell micronucleus test was conducted to understand the genetic toxicity of LPSp.The result of acute oral toxicity test showed that LPSp is defined with no toxicity (LD505 000mg/kg);which of the skin and eye irritation test showed LPSp hasn't irritation reaction and hypersensitivity for skin and eye (the integration of both skin and eye are 0);which of skin alleray test showed LPSp is not the sensitinogen for guinea pig (both integration and ratio of skin reaction are 0);which of sal-monella typhimurium/reverse mutation assay was negative (P0.05);which of cell micronucleus test was negative (compared with negative control P0.05,compared with positive control P0.01).It is concluded that LPSp is very safe for these animals in our experiments;it is no toxicity,no irritation,no hypersensitivity and no genetic toxicity.
出处 《基因组学与应用生物学》 CAS CSCD 北大核心 2011年第2期175-183,共9页 Genomics and Applied Biology
基金 广西自然科学基金项目(桂科青0135012) 广西医科大学博士基金项目(2004)共同资助
关键词 成团泛菌 细菌脂多糖(LPS) 毒性试验 回复突变试验 微核试验 Pantoea agglomerans LPS Toxicity test Reverse mutation assay Micronucleus test
  • 相关文献

参考文献19

  • 1Beutler B., and Rietschel E.T., 2003, Innate immune sensing and its roots: The story of endotoxin, Nature Rev. Immunol., 3: 169-176.
  • 2Caroff M., and Karibian D., 2003, Structure of bacterial lipopolysaccharides, Carbohydr Res., 338(23): 2431-2447.
  • 3Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B., 1975, An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci., USA, 72(9): 3666-3670.
  • 4Casella C.R., and Mitchell T.C., 2008, Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant, Cell Mol. Life Sci., 65(20): 3231-3240.
  • 5D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X.J, Kubin M., and Trinchieri G., 1993, Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells, J. Exp. Med., 178(3): 1041-1048.
  • 6de Gregorio E., Tritto E., and Rappuoli R., 2008, Alum adjuvanticity: Unraveling a century old mystery, Eur. J. Immunol., 38(8): 2068-2071.
  • 7Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., and Baldridge J.R., 2003, Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529, Expert Rev.Vaccines, 2(2): 219-229.
  • 8Galanos C., Ltideritz O., Rietschel E.T., Westphal O., Brade H., Brade L., Freudenberg M., Schade U., Imoto M., Yoshimura H., Kusumoto S., and Shiba T., 1985, Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities, Eur. J. Biochem., 148(1): 1-5.
  • 9Garcon N., Chomez P., and van Mechelen M., 2007, Glaxo-SmithKline adjuvant systems in vaccines: Concepts, achievements and perspectives, Expert Rev. Vaccines, 6(5): 723-739.
  • 10Goto S., Sakai S., Kera J., Suma Y., Soma G.I., and Takeuchi S., 1996, Intradermal administration of lipopolysaccharide in treatment of human cancer, Cancer Immunol Immunother, 42(4): 255-261.

二级参考文献41

  • 1徐学瑛 李元 等.一个改进的体液免疫测定方法-溶血素测定法[J].药学学报,1979,14(7):443-443.
  • 2[1]Coley W B.The treatment of malignant tumors by repeated inoculations of erysipelas:With a report of ten original cases.Practitioner,1909,83:589-613.
  • 3[2]Carswell EA.Old LJ,Kassel PI,et al.An endotoxin-induced serum factor that causes necrosis of tumors.Proc Natl Acad Sci USA,1975,72:3 666-3 670.
  • 4[3]Lukasiewicz J,Lugowski C.Biologic activity of lipopolysaccharides.Postepy Hig Med Dosw,2003,57(1):33-53.
  • 5[4]Galanos C,Luderitz O,Westphal O.A new method for the extraction of R lipopolysaccharides.Eur J Biochem,1969,9:245-249.
  • 6[5]H Schagger,G von Jagow,Anal.Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.Biochem,1987,166:368-379.
  • 7[6]R Chaby SR,Sarfati,L Szabo.Colorimetric estimation of 3-deoxy-D-mannooctulosonic acid in oligosaccharides with diphenylamine.Anat.biochem,1974,58:123-129.
  • 8[7]Boas NF.Method for determination of hexosamine in tissue.J Biol Chem,1953,204:553.
  • 9[8]Dubois M,Gilles DA,Hamilton JK,et al.Colorimetric method for the determination of sugars and related substances.Anal Chem,1956,28:350-356.
  • 10[9]Chen K,Toribara T Y,Warner H.Microdetermination of phosphorus.Anal Chem,1956,28:1 756-1 758.

共引文献13

同被引文献42

  • 1金生,张大志,陈压西.Toll样受体研究进展与临床免疫[J].重庆医学,2004,33(9):1423-1426. 被引量:3
  • 2俞永新.国内外狂犬病疫苗的发展和现状[J].上海预防医学,2006,18(5):216-218. 被引量:27
  • 3王健,冷静,王启辉.LPSp辅佐HBsAg诱导机体产生特异性抗体的机制[J].细胞与分子免疫学杂志,2007,23(6):559-561. 被引量:6
  • 4Leng J,Wang QH,Wang J,et al.The regulatory effect of LPSp on hepatitis B surface antibody[J].Chin J Chro Dis,2004,3(4):84-88.
  • 5Beutler B,Rietschel ET.Innate immune sensing and its roots:the story of endotoxin[J].Nat Rev Immunol,2003,3(2):169-176.
  • 6Casella CR,Mitchell TC.Putting endotoxin to work for us:monophosphoryl lipid A as a safe and effective vaccine adjuvant[J].Cell Mol Life Sci,2008,65(20):3231-3240.
  • 7Evans JT,Cluff CW,Johnson DA,et al.Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529[J].Expert Rev Vaccines,2003,2(2):219-229.
  • 8Caroff M,Karibian D.Structure of bacterial lipopolysaccharides[J].Carbohydr Res,2003,338(23):2431-2447.
  • 9Montminy SW,Khan N,McGrath S,et al.Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response[J].Nat Immunol,2006,7(10):1066-1073.
  • 10Iwamoto I,Goto S,Kera J,et al.Mechanistic analysis of high antitumor effect of intradermal administration of lipopolysaccharide from Pantoea Agglomerans[J].Med Oncol,1996,13(2):103-109.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部